Humacyte, Inc. (HUMA) Revenue History
Annual and quarterly revenue from 2019 to 2024
Compound Annual Growth Rate (CAGR)
Loading revenue history...
HUMA Revenue Growth
HUMA Revenue Analysis (2019–2024)
As of May 8, 2026, Humacyte, Inc. (HUMA) generated trailing twelve-month (TTM) revenue of $8.8 million. The most recent quarter (Q3 2025) recorded $753,000 in revenue, up 150.2% sequentially.
Looking at the longer-term picture, HUMA's historical revenue data shows various trends over time. The company achieved its highest annual revenue of $6.2 million in 2019.
When compared to Healthcare sector peers including TELA (+12.2% YoY), NVCR (+8.5% YoY), and ATRC (+15.0% YoY). Compare HUMA vs TELA →
HUMA Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| HUMACurrent | $9M | - | - | - | |
 TELA | $69M | +12.2% | +35.0% | -49.2% | |
 NVCR | $655M | +8.5% | +5.8% | -23.5% | |
 ATRC | $535M | +15.0% | +20.9% | -0.6% | |
 ANGO | $292M | +7.3% | +2.1% | -13.7% | |
 AORT | $441M | +17.6% | +11.8% | 6.1% |
HUMA Historical Revenue Data (2019–2024)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $0 | - | $-7,190,000 | - | $-114,398,000 | - |
| 2023 | $0 | -100.0% | $-76,550,000 | - | $-100,047,000 | - |
| 2022 | $1.6M | +23.9% | $-6,690,000 | -427.5% | $-84,578,000 | -5404.3% |
| 2021 | $1.3M | -15.3% | $-60,078,000 | -4756.8% | $-81,208,000 | -6429.8% |
| 2020 | $1.5M | -75.9% | $-52,587,000 | -3527.0% | $-64,599,999 | -4332.7% |
| 2019 | $6.2M | - | $-69,416,000 | -1122.0% | $-85,691,000 | -1385.0% |
See HUMA's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs HUMA Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare HUMA vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonHUMA — Frequently Asked Questions
Quick answers to the most common questions about buying HUMA stock.
Is HUMA's revenue growth accelerating or slowing?
HUMA TTM revenue: $9M. YoY growth: N/A. 5-year CAGR: N/A.
What is HUMA's long-term revenue growth rate?
Humacyte, Inc.'s 5-year revenue CAGR of N/A reflects the variable expansion pattern. Current YoY growth of N/A is near this long-term average.
How is HUMA's revenue distributed by segment?
HUMA reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2019-2024 are available for download. Segment mix reveals concentration and diversification trends.